ORIGINAL ARTICLE

CLINICAL GENETICS WILEY

De novo variants in neurodevelopmental disorders—experiences from a tertiary care center

Theresa Brunet[1] | Robert Jech[2] | Melanie Brugger[1,3] | Reka Kovacs[1] | Bader Alhaddad[1] | Gloria Leszinski[1] | Korbinian M. Riedhammer[1,4] | Dominik S. Westphal[1,5] | Isabella Mahle[1] | Katharina Mayerhanser[1] | Matej Skorvanek[6,7] | Sandrina Weber[8,9] | Elisabeth Graf[1,10] | Riccardo Berutti[1] | Ján Necpál[11] | Petra Havránková[2] | Petra Pavelekova[6,7] | Maja Hempel[12] | Urania Kotzaeridou[13] | Georg F. Hoffmann[13] | Steffen Leiz[14] | Christine Makowski[15] | Timo Roser[16] | Sebastian A. Schroeder[16] | Robert Steinfeld[17] | Gertrud Strobl-Wildemann[18] | Julia Hoefele[1] | Ingo Borggraefe[16] | Felix Distelmaier[19] | Tim M. Strom[1] | Juliane Winkelmann[1,8,20,21] | Thomas Meitinger[1] | Michael Zech[1,8] | Matias Wagner[1,8]

[1]Institute of Human Genetics, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany

[2]Department of Neurology, Charles University, 1st Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic

[3]Institute of Human Genetics, University Hospital, Ludwig Maximilians University of Munich, Munich, Germany

[4]Department of Nephrology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany

[5]Medical Department I, Cardiology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany

[6]Department of Neurology, P. J. Safarik University, Kosice, Slovakia

[7]Department of Neurology, University Hospital L. Pasteur, Kosice, Slovakia

[8]Institute of Neurogenomics, Helmholtz Zentrum München, Neuherberg, Germany

[9]Paracelsus-Elena-Klinik, Kassel, Germany

[10]Institute of Human Genetics, Helmholtz Zentrum München, Neuherberg, Germany

[11]Department of Neurology, Zvolen Hospital, Zvolen, Slovakia

[12]Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

[13]Division of Child Neurology and Inherited Metabolic Diseases, Centre for Paediatrics and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany

[14]Divison of Neuropediatrics, Clinic for Children and Adolescents Dritter Orden, Munich, Germany

[15]Department of Pediatrics, Technische Universität München, Munich, Germany

[16]Department of Paediatric Neurology and Developmental Medicine, Hauner Children's Hospital, University of Munich, Munich, Germany

[17]Division of Pediatric Neurology, University Children's Hospital Zurich, Zurich, Switzerland

[18]Praxis für Humangenetik, Ulm, Germany

[19]Department of General Pediatrics, Neonatology and Pediatric Cardiology, Heinrich-Heine-University, Düsseldorf, Germany

[20]Munich Cluster for Systems Neurology (SyNergy), Munich, Germany

[21]Neurogenetics, Technische Universität München, Munich, Germany

Correspondence
Theresa Brunet, Institute of Human Genetics, School of Medicine, Technical University Munich, Munich, Germany.
Email: theresa.brunet@mri.tum.de

Abstract

Up to 40% of neurodevelopmental disorders (NDDs) such as intellectual disability, developmental delay, autism spectrum disorder, and developmental motor abnormalities have a documented underlying monogenic defect, primarily due to *de novo* variants. Still, the overall burden of *de novo* variants as well as novel disease genes in NDDs await discovery. We performed parent-offspring trio exome sequencing in 231 individuals with NDDs. Phenotypes were compiled using human phenotype ontology terms. The overall diagnostic yield was 49.8% (n = 115/231) with *de novo* variants contributing to more than 80% (n = 93/115) of all solved cases. *De novo* variants affected 72 different—mostly constrained—genes. In addition, we identified putative pathogenic variants in 16 genes not linked to NDDs to date. Reanalysis performed in 80 initially unsolved cases revealed a definitive diagnosis in two additional cases. Our study consolidates the contribution and genetic heterogeneity of *de novo* variants in NDDs highlighting trio exome sequencing as effective diagnostic tool for NDDs. Besides, we illustrate the potential of a trio-approach for candidate gene discovery and the power of systematic reanalysis of unsolved cases.

KEYWORDS

autism, candidate gene, de novo variant, exome sequencing, intellectual disability, neurodevelopmental disorder, reanalysis

1 | INTRODUCTION

Neurodevelopmental disorders (NDDs) comprise a heterogeneous group of conditions affecting brain development and function and can manifest in impaired cognition, behavior, language, and motor functioning.[1] In accordance to "Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition"[2] (DSM-5), NDD encompasses intellectual developmental disorders, communication disorders, autism spectrum disorders, attention-deficit/hyperactivity disorders, specific learning disorders, and motor disorders.[2] Furthermore, patients with NDDs often demonstrate additional, (non-) neurological comorbidities.[3]

While NDDs can have numerous causes such as fetal exposure to toxicants, perinatal asphyxia and environmental contaminants, monogenic conditions make an essential contribution to the etiology of NDD.[1] The genetic etiology underlying NDD is extremely heterogeneous extending from large chromosomal aberration to single-nucleotide variants (SNVs) in >1000 of genes.[4] Nevertheless, theoretical calculations indicate that over 500 novel NDD genes remain to be discovered.[5] It has been widely acknowledged in large-scale sequencing studies that variants in protein-coding genes that have arisen *de novo* are enriched in individuals with NDDs and constitute the major cause of NDDs in outbred populations.[6-14] 42%–48% of individuals with a NDD are thought to harbor a causative *de novo* variant in known as well as yet-undiscovered disease genes.[13] However, the burden of *de novo* variants in NDD has not yet been fully illuminated.[14]

With the aim to better elucidate the genetic spectrum of (*de novo*) variants underlying rare NDDs, we describe detailed clinical and genetic findings in 231 individuals with NDDs who underwent trio exome sequencing in a single tertiary care genetic center.

2 | MATERIALS AND METHODS

2.1 | Study design

We retrospectively analyzed 231 individuals with NDDs in whom trio exome sequencing was performed in our institute. The families were recruited over a period of 3 years (August 2017 until July 2020) from different centers for human genetics, neuropediatrics, and neurology in Germany, Switzerland, Slovakia and Czech Republic. 177 (76.6%) of these 231 trios have not been published previously. Individuals were found eligible for this study if they had (1) a symptom or a constellation of symptoms consistent with a NDD (in accordance with the diagnostic criteria of "Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition"[2]) and (2) no prior genetic diagnosis. We obtained and thoroughly reviewed clinical records of all individuals and applied the human phenotype ontology (HPO) to systematically characterize the individuals' phenotype.[15] As previously published, individuals were categorized to one of two categories based on their clinical presentation: (1) isolated NDD or (2) NDD plus associated conditions defined as any additional neurological, systemic, syndromic, or other clinical

characteristic, for example, microcephaly or neutropenia.[16] Family history was collected by the referring clinician where applicable and a family history was considered as positive when a first-degree relative had a NDD.

All participants or their guardians gave written informed consent for exome sequencing and the publication of relevant findings. The study was performed in agreement with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Declaration of Helsinki, and was approved by the respective local ethics committees.

2.2 | Trio exome sequencing

Exome sequencing was performed for all affected individuals and their parents using a SureSelect Human All Exon Kit 60 Mb, V6 (Agilent, Santa Clara, California) for enrichment and a Illumina NovaSeq6000 or Illumina HiSeq4000 system (Illumina, San Diego, California). Reads were aligned to the UCSC human reference assembly (hg19) with BWA v.0.7.8. SNVs and small insertions and deletions were detected using SAMtools v.0.1.19.[17] Copy number variations (CNVs) were detected with ExomeDepth and Pindel.[18,19] Mitochondrial DNA (mtDNA) variants were assessed using off-target reads as previously described.[20] Variants were analyzed in the in-house exome variant analysis database (EVAdb) using I) a recessive filter for homozygous and compound heterozygous variants with a minor allele frequency (MAF, according to in-house database with over 20 000 exomes) < 1%, II a filter for X chromosomal variants with a MAF < 0.1% and III) a filter for de novo variants with a MAF < 0.01%. IV) A phenotype-based search was conducted by performing an OMIM full term search using the three most characteristic phenotypic traits to establish a gene list. The filter queries variants with a MAF < 0.1%. In addition, CNVs with a MAF < 0.01 and mtDNA variants with a MAF < 1% were assessed. Identified variants were classified according to the American College of Medical Genetics and Genomics (ACMG) guidelines.[21-23]

Only cases with likely pathogenic or pathogenic variants as per ACMG (in the following designated "disease-causing") in established disease genes for NDDs were considered as solved and were reflected in the overall diagnostic yield. All genes with "strong" or "definitive" evidence for gene-disease relationship as defined by the Clinical Genome Resource (ClinGen) were considered as established disease genes.[24] Individuals with variants in candidate genes subsequently established as disease genes, were also categorized as solved and assigned to the overall yield. Individuals with (1) negative results (i.e., no variant[s] prioritized), (2) variants of uncertain significance (VUS) in NDDs associated genes or (3) variants in candidate genes for NDDs (as of November 2020) were summarized as unsolved cases. Reanalysis using updated variant annotation and newly discovered gene disease associations was performed for all cases with negative results older than ≥1 year (August 2017–September 2019).

For all established disease genes containing causative de novo variants, constraint metrics (pLIs and Z-scores) were extracted from Genome Aggregation Database (gnomAD) v2.1.1 to evaluate gene tolerance to loss-of-function or missense variants.[25] As recommended by gnomAD, we used pLI > 0.9 for loss-of-function variants and Z-score > 3.09 for missense variants as constraint threshold values.[26]

3 | RESULTS

3.1 | Demographic features and clinical findings

We performed parent-offspring trios in 231 individuals (117 females and 114 males) with NDDs over a period of 3 years. Age range was from 1 months to 46 years (median: 5.3 years) with 90% of individuals falling between 0 and 18 years. Parental consanguinity was reported in three cases. Information on the family history was available in 86/231 (37.2%) individuals. 9/86 (10.5%) cases had a positive family history with an affected first-degree relative. A monogenic disorder could genetically be established in a single cases with a positive family history, a de novo PTPN11 was identified by trio analysis whereas the autism spectrum disorder remained without a monogenic explanation in the brother.

Clinical characteristics were captured using HPO terms (Table S1).[15] Among all 231 individuals, a total of n = 1291 HPO terms (median pro sample: 5, [interquartile range: 4–7]) were assigned. In summary, NDD phenotypes comprised global developmental delay (n = 175, 75.8%), intellectual disability (n = 46, 19.9%), speech delay (n = 28, 12.1%), motor delay (n = 26, 11.3%) and autistic behavior/autism (n = 26, 11.3%). Common additional features included seizures (n = 70, 30.3%), dystonia (n = 59, 25.5%), muscular hypotonia (n = 42, 18.2%), microcephaly (n = 32, 13.9%), cerebral palsy (n = 24, 10.4%), ataxia (n = 23, 10.0%), abnormal facial shape (n = 23, 10.0%), spasticity (n = 20, 8.7%) and hearing impairment (n = 13, 5.6%). Figure 1(A) gives a summary of the most frequent clinical features encountered in our cohort. The majority of individuals had NDDs plus associated conditions (n = 213/231, 92.2%), while only n = 18/231 (7.8%) individuals had isolated NDD without any additional features. The proportion of cases with NDDs plus associated conditions was higher in the subgroup with autosomal recessive inheritance (n = 19/19, 100%) in comparison with those with de novo variants (n = 89/93, 95.7%).

3.2 | Diagnostic yield

Overall, trio exome sequencing identified disease-causing variants in developmental disorder associated genes in 115/231 individuals reflecting an overall yield of 49.8%. The diagnostic yield was significantly higher in individuals with NDD plus associated conditions (n = 111/213, 52.1%) in comparison to individuals with isolated NDD (n = 4/18, 22.2%, p = 0.0247, Fisher's exact test).[27] 59/117 female individuals (50.4%) and 56/114 male individuals (49.1%) received a genetic diagnosis. In the group of individuals ≥18 years (n = 24/231, 10.4%), the overall yield was 50.0%. In the group of individuals <18 years (n = 206/231), the overall yield was 49.5%.

(A)

(B)

FIGURE 1 Phenotypic characterization and results of trio exome sequencing in n = 231 individuals with NDDs. (A) Distribution of the most frequent HPO categories among individuals undergoing trio exome sequencing. (B) The pie chart illustrates the results of the trio exome sequencing study (231 individuals, 426 parents) with an overall diagnostic yield of 49.8%. Solved cases were defined by the presence of disease-causing variants in established NDD-associated genes. The bar chart on the right visualizes the distribution of all disease-causing variants based on the inheritance mode with *de novo* variants representing the most frequent inheritance. 50.2% of all cases remained unsolved which included cases with negative results (i.e., no variant[s] prioritized) as well as cases with VUSs and cases with variants in candidate genes. HPO, human phenotype ontology; NDDs, neurodevelopmental disorders; VUSs, variants of uncertain significance [Colour figure can be viewed at wileyonlinelibrary.com]

In the majority of individuals (n = 93/115, 80.9%), the molecular diagnosis based on *de novo* variants in genes either associated with autosomal dominant disorders (n = 82/115, 71.3%) or with X-linked disorders (n = 11/115, 9.6%). In two cases, variants in genes/chromosomal locations linked to autosomal dominant disorders (*KMT2D*, Chromosome 16q23.2–23.3 deletion) were inherited from an affected parent (n = 2/115, 1.7%) and in one case, a variant in a gene associated with a X-linked disorder (*MECP2* duplication) was inherited from the unaffected mother (n = 1/115, 0.9%). 19/115 individuals (16.5%) harbored homozygous (n = 7/115, 6.1%) or compound heterozygous (n = 12/115, 10.4%) variants in genes related to autosomal recessive disorders. 3/7 patients with homozygous variants had a consanguineous background. A disease causing CNV (deletions >500 kb, duplications >2 Mb) was found in seven individuals leading to an overall burden of CNVs of 3.0% (n = 7/231).

116/231 individuals (50.2%) remained unsolved after trio exome sequencing. The unsolved group subsumed individuals with negative results (n = 92/231, 39.8%), individuals with VUS in DD/ID associated genes (n = 8/231, 3.5%) and individuals with variants in novel or known candidate genes for DD/ID (n = 16/231, 6.9%). These overall results are summarized in Figure 1(B).

3.3 | Characteristics of *de novo* variants

40.3% (n = 93/231) of all individuals or 80.9% of all solved cases (n = 93/115), respectively, harbored *de novo* variants in protein-coding disease genes, either in autosomal (n = 81/93, 87.1%) or X-linked genes (n = 12/93, 12.9%). Individuals with *de novo* variants in autosomal genes (n = 81) subdivided into 43 females and 38 males. Among

FIGURE 2 Characteristics of *de novo* variants in known disease genes identified in 93 individuals. (A) Spectrum and number of identified variant types with missense variants representing the most frequent variant type. (B) Spectrum of genes/chromosomal regions containing disease-causing *de novo* variants. The counts of individuals harboring a variant per gene/chromosomal region are shown. Genes implicated in autosomal dominant disorders are marked in blue, while genes associated with X-linked disorders are colored in green. By using trio exome sequencing, a total of 72 distinct disease entities were established. With four individuals carrying a variant in *ZEB2*, Mowat-Wilson syndrome was the most frequent molecular diagnosis. (C) Probability of being loss-of-function intolerant (pLI) score distribution of genes with *de novo* variants in autosomal and X-linked according to constraint metrics of gnomAD. Genes harboring loss-of-function (nonsense, frameshift, canonical splice site variants) variants or CNVs are highlighted in blue. (D) Missense Z-score distribution of genes with *de novo* variants in autosomal and X-linked according to constraint metrics of gnomAD. Genes harboring missense variants and in-frame deletions are highlighted in black. CNVs, Copy number variations [Colour figure can be viewed at wileyonlinelibrary.com]

individuals with *de novo* variants in X-linked genes (n = 12) were four males and eight females. We identified a variety of variant types with missense variants being the predominant type (n = 54/93, 58.1%) followed by frameshift variants (n = 17/93, 18.3%), nonsense variants (n = 10/93, 10.8%), canonical splice site variants (n = 3/93, 3.2%), indels (n = 2/93, 2.2%), intragenic deletions (<10 kb) (n = 2/93, 2.2%), large deletions >500 kb (n = 3/93, 3.2%) and large duplications >2 Mb

(n = 2/03, 2.2%) (Figure 2(A)). Parental mosaicism was identified in one family (individual 47), in which the frameshift variant in *KMT2B* was identified as low-level mosaicism (in 1/216 reads) in the healthy mother. We did not encounter any cases of postzygotic mosaicism in the index patients.

A wide spectrum of diagnoses was established based on the molecular findings. In total, 72 distinct diagnoses were made with the

TABLE 1 List of all (likely) pathogenic *de novo* variants identified in this cohort (n = 93)

Individual	Gene/locus	Transcript	Variant	Zygosity	Variant type	CADD score	ACMG classification	Diagnosis	OMIM phenotype
1	ACTB	NM_001101.3	c.4G>T, p.(Asp2Tyr)	Heterozygous	Missense	25.4	Likely pathogenic	Baraitser-Winter syndrome 1	#243310
2	ADCY5	NM_183357.2	c.1322C>T, p.(Ala441Val)	Heterozygous	Missense	33	Likely pathogenic	Dyskinesia, familial, with facial myokymia	#606703
3	ADCY5	NM_183357.2	c.2071A>G, p.(Lys691Glu)	Heterozygous	Missense	29.1	Likely pathogenic	Dyskinesia, familial, with facial myokymia	#606703
4	ANKRD11	NM_001256182.1	c.2704G>T, p.(Glu902*)	Heterozygous	Nonsense	36	Pathogenic	KBG syndrome	#148050
5	ARID1B	NM_020732.3	c.2191_2192dup, p.(Pro732Serfs*14)	Heterozygous	Frameshift		Pathogenic	Coffin-Siris syndrome 1	#135900
6	ARID1B	NM_020732.3	c.4009C>T, p.(Arg1337*)	Heterozygous	Nonsense	47	Pathogenic	Coffin-Siris syndrome 1	#135900
7	ARID1B	NM_020732.3	c.6382C>T, p.(Arg2128*)	Heterozygous	Nonsense	52	Pathogenic	Coffin-Siris syndrome 1	#135900
8	ATP1A3	NM_152296.4	c.2443G>A, p.(Glu815Lys)	Heterozygous	Missense	34	Pathogenic	CAPOS syndrome	#601338
9	ATP1A3	NM_152296.5	c.266G>C, p.(Gly89Ala)	Heterozygous	Missense	24.2	Likely pathogenic	CAPOS syndrome	#601338
10	AUTS2	NM_015570.4	c.1604A>C, p.(His535Pro)	Heterozygous	Missense	28.3	Likely pathogenic	Mental retardation, autosomal dominant 26	#615834
11	BCL11B	NM_022898.1	c.1835del, p.(Ser612Thrfs*40)	Heterozygous	Frameshift		Pathogenic	Intellectual developmental disorder with dysmorphic facies, speech delay, and T-cell abnormalities	#618092
12	CDKL5	NM_001323289.2	Deletion exon 16–18	Heterozygous	Intragenic deletion		Pathogenic	Epileptic encephalopathy, early infantile, 2	#300672
13	CHD2	NM_001271.3	c.3454C>G, p.(Arg1152Gly)	Heterozygous	Missense	24.6	Likely pathogenic	Epileptic encephalopathy, childhood-onset	#615369
14	CHD4	NM_001273.2	c.637A>G, p.(Ser213Gly)	Heterozygous	Missense	24.4	Likely pathogenic	Sifrim-Hitz-Weiss syndrome	#617159
15	CHD8	NM_001170629.1	c.4378C>T, p.(Arg1460*)	Heterozygous	Nonsense	43	Pathogenic	CHD8-associated disorder	#615032
16	Chromosome 14q32.2 deletion (~1 Mb)		chr14:100317190_101351124del	Heterozygous	CNV		Pathogenic	Chromosome 14q32.2 deletion	Not listed
17	Chromosome 17p13.1 deletion (~500 kb)		chr17:7554837_8093457del	Heterozygous	CNV		Pathogenic	Chromosome 17p13.1 deletion syndrome	#613776

TABLE 1 (Continued)

Individual	Gene/locus	Transcript	Variant	Zygosity	Variant type	CADD score	ACMG classification	Diagnosis	OMIM phenotype
18	Chromosome 6q21-6q22.31 duplication (~16 Mb)		chr6:106960217_123957919dup	Heterozygous	CNV		Pathogenic	Chromosome 6q21-6q22.31 duplication	Not listed
19	Chromosome Xp11.23-p11.22 duplication (~2 Mb)		chrX:46736940_48693933dup	Heterozygous	CNV		Pathogenic	Chromosome Xp11.23-p11.22 duplication syndrome	# 300801
20	Chromosome 15q11-q13 deletion (~5 Mb)		chr15:23572076_28600151del	Heterozygous	CNV		Pathogenic	Prader-Willi syndrome	# 176270
21	CTCF	NM_006565.3	c.958C>G, p.(Arg320Gly)	Heterozygous	Missense	32	Likely pathogenic	Mental retardation, autosomal dominant 21	# 615502
22	CYFIP2	NM_014376.2	c.1363G>C, p.(Ala455Pro)	Heterozygous	Missense	29.5	Pathogenic	Epileptic encephalopathy, early infantile, 65	# 618008
23	CYFIP2	NM_001037332.2	c.2095G>C, p.(Asp699His)	Heterozygous	Missense	33	Pathogenic	Epileptic encephalopathy, early infantile, 65	# 618008
24	DDX3X	NM_001356.3	c.1148C>G, p.(Ala383Gly)	Heterozygous	Missense	26.6	Pathogenic	Mental retardation, X-linked 102	# 300958
25	DDX3X	NM_001356.3	c.977G>A, p.(Arg326His)	Heterozygous	Missense	32	Pathogenic	Intellectual developmental disorder, X-linked, syndrome, Snijders Blok type	# 300958
26	DNM1L	NM_005690.4	c.428C>G, p.(Thr143Arg)	Heterozygous	Missense	29.4	Pathogenic	Encephalopathy due to defective mitochondrial and peroxisomal fission-1	# 614388
27	DNM1L	NM_005690.4	c.1207C>T, p.(Arg403Cys)	Heterozygous	Missense	35	Pathogenic	Encephalopathy, lethal, due to defective mitochondrial peroxisomal fission 1	# 614388
28	EFTUD2	NM_004247.4	Deletion Exon 10	Heterozygous	Intragenic deletion		Likely pathogenic	Mandibulofacial dysostosis, Guion-Almeida type	# 610536
29	GNAO1	NM_138736.2	c.626G>A, p.(Arg209His)	Heterozygous	Missense	35	Pathogenic	Neurodevelopmental disorder with involuntary movements	# 617493

(Continues)

TABLE 1 (Continued)

Individual	Gene/locus	Transcript	Variant	Zygosity	Variant type	CADD score	ACMG classification	Diagnosis	OMIM phenotype
30	GNAO1	NM_020988.3	c.625C>T, p.(Arg209Cys)	Heterozygous	Missense	35	Pathogenic	Neurodevelopmental disorder with involuntary movements	# 617493
31	GNAO1	NM_020988.3	c.625C>T, p.(Arg209Cys)	Heterozygous	Missense	35	Pathogenic	Neurodevelopmental disorder with involuntary movements	# 617493
32	HECW2	NM_020760.1	c.3829 T>C, p.(Tyr1277His)	Heterozygous	Missense	29.2	Likely pathogenic	Neurodevelopmental disorder with hypotonia, seizures, and absent language	# 617268
33	HK1	NM_033498.2	c.1382C>T, p.(Thr461Met)	Heterozygous	Missense	34	Pathogenic	Neurodevelopmental disorder with visual defects and brain anomalies	# 618547
34	HNRNPH2	NM_019597.4	c.85C>T, p.(Arg29Cys)	Hemizygous	Missense	25	Likely pathogenic	Mental retardation, X-linked, syndromic, Bain type	# 300986
35	HNRNPU	NM_004501.3	c.575C>A, p.(Ser192*)	Heterozygous	Nonsense	37	Pathogenic	Epileptic encephalopathy, early infantile, 54	# 617391
36	IFIH1	NM_022168.3	c.2159G>A, p.(Arg720Gln)	Heterozygous	Missense	34	Pathogenic	Aicardi-Goutieres syndrome 7	# 615846
37	IMPDH2	NM_000884.2	c.338G>A, p.(Gly113Glu)	Heterozygous	Missense	33	Pathogenic	IMPDH2-associated disorder	Not listed
38	ITPR1	NM_002222.5	c.805C>T, p.(Arg269Trp)	Heterozygous	Missense	34	Pathogenic	Gillespie syndrome	# 206700
39	KCNH1	NM_002238.3	c.1405G>A, p.(Gly469Arg)	Heterozygous	Missense	34	Pathogenic	Zimmermann-Laband syndrome 1	# 135500
40	KCNT1	NM_020822.2	c.1283G>A, p.(Arg428Gln)	Heterozygous	Missense	34	Pathogenic	Epileptic encephalopathy, early infantile, 14	# 614959
41	KDM3B	NM_016604.3	c.2828G>A, p.(Arg943Gln)	Heterozygous	Missense	34	Pathogenic	Diets-Jongmans syndrome	# 618846
42	KIF11	NM_004523.3	c.2922G>A, p.(?)	Heterozygous	Splice	8.012	Pathogenic	Microcephaly with or without chorioretinopathy, lymphedema, or mental retardation	# 152950
43	KIF1A	NM_004321.6	c.760C>T, p.(Arg254Trp)	Heterozygous	Missense	34	Pathogenic	NESCAV syndrome	# 614255

TABLE 1 (Continued)

Individual	Gene/locus	Transcript	Variant	CADD score	Variant type	Zygosity	ACMG classification	Diagnosis	OMIM phenotype
44	KIF5C	NM_004522.2	c.420G>A, p.(Arg141Gln)	34	Missense	Heterozygous	Pathogenic	Cortical dysplasia, complex, with other brain malformations 2	#615282
45	KMT2A	NM_001197104.1	c.6463C>G, p.(Pro2155Ala)	22.9	Missense	Heterozygous	Likely pathogenic	Wiedemann-Steiner syndrome	#605130
46	KMT2B	NM_014727.1	c.1633C>T, p.(Arg545*)	36	Nonsense	Heterozygous	Pathogenic	Dystonia 28, childhood-onset	#617284
47	KMT2B	NM_014727.1	c.521dup, p.(Thr176Aspfs*8)[a]		Frameshift	Heterozygous	Pathogenic	Dystonia 28, childhood-onset	#617284
48	KMT2B	NM_014727.1	c.4847C>T, p.(Ala1616Val)	32	Missense	Heterozygous	Pathogenic	Dystonia 28, childhood-onset	#617284
49	KMT2C	NM_170606.2	c.1951_1952del, p.(Glu651Lysfs*3)		Frameshift	Heterozygous	Pathogenic	Kleefstra syndrome 2	#617768
50	KMT2D	NM_003482.3	c.15163_15168dup, p.(Asp5055_Leu5056dup)		Indel	Heterozygous	Pathogenic	Kabuki syndrome 1	#147920
51	MORC2	NM_014941.3	c.995A>G, p.(Tyr332Cys)	28.6	Missense	Heterozygous	Likely pathogenic	Charcot–Marie–Tooth disease, axonal, type 2Z	#616688
52	MSL3	NM_078629.3	c.1466+1G>A, p.?	33	Splice	Heterozygous	Pathogenic	Basilicata-Akhtar syndrome	#301032
53	MSL3	NM_078629.3	c.1314C>A, p.(Tyr438*)	32	Nonsense	Hemizygous	Pathogenic	Basilicata-Akhtar syndrome	#301032
54	NONO	NM_007363.4	c.90_114del, p.(Gln30Hisfs*18)		Frameshift	Hemizygous	Pathogenic	Mental retardation, X-linked, syndromic 34	#300967
55	NSD1	NM_022455.4	c.2289_2317dup, p.(Ala773Valfs*5)		Frameshift	Heterozygous	Pathogenic	Sotos syndrome 1	#117550
56	NUS1	NM_138459.3	c.238_263del, p.(Ala80Argfs*45)		Frameshift	Heterozygous	Pathogenic	Mental retardation, autosomal dominant 55, with seizures	#617831
57	PAK1	NM_002576.5	c.1427 T>C, p.(Ile476Thr)	29.6	Missense	Heterozygous	Likely pathogenic	Intellectual developmental disorder with macrocephaly, seizures, and speech delay	#618158
58	PDHA1	NM_000284.3	c.787C>G, p.(Arg263Gly)	24.6	Missense	Heterozygous	Pathogenic	Pyruvate dehydrogenase E1-alpha deficiency	#312170

(Continues)

TABLE 1 (Continued)

Individual	Gene/locus	Transcript	Variant	Zygosity	Variant type	CADD score	ACMG classification	Diagnosis	OMIM phenotype
59	PPP2R5D	NM_006245.3	c.592G>A, p.(Glu198Lys)	Heterozygous	Missense	33	Pathogenic	Mental retardation, autosomal dominant 35	# 616355
60	PTPN11	NM_002834.3	c.166A>G, p.(Ile56Val)	Heterozygous	Missense	25.1	Pathogenic	Noonan syndrome 1	# 163950
61	PTPN11	NM_002834.3	c.417G>C, p.(Glu139Asp)	Heterozygous	Missense	27.4	Pathogenic	Noonan syndrome 1	# 163950
62	PTPN11	NM_002834.4	c.1510A>G, p.(Met504Val)	Heterozygous	Missense	26.4	Pathogenic	Noonan syndrome 1	# 163950
63	PUF60	NM_078480.2	c.1100del, p.(Leu367CysfsTer*17)	Heterozygous	Frameshift		Pathogenic	Verheij Syndrome	# 615583
64	PURA	NM_005859.4	c.565G>C, p.(Ala189Pro)	Heterozygous	Missense	28.6	Likely pathogenic	Mental retardation, autosomal dominant 31	# 616158
65	PURA	NM_005859.4	c.366_367dup, p.(Gln123Argfs*103)	Heterozygous	Frameshift		Pathogenic	Mental retardation, autosomal dominant 31	# 616158
66	PURA	NM_005859.4	c.640G>T, p.(Glu214*)	Heterozygous	Nonsense	39	Pathogenic	Mental retardation, autosomal dominant 31	# 616158
67	RHOBTB2	NM_001160036.1	c.1519C>T, p.(Arg507Cys)	Heterozygous	Missense	34	Pathogenic	Early infantile epileptic encephalopathy 64	# 618004
68	RHOBTB2	NM_001160036.2	c.1448G>A, p.(Arg483His)	Heterozygous	Missense	31	Pathogenic	Epileptic encephalopathy, early infantile, 64	# 618004
69	SET	NM_001122821.1	c.457_458del, p.(Ser153Glnfs*7)	Heterozygous	Frameshift		Pathogenic	Mental retardation, autosomal dominant 58	# 618106
70	SETD1B	NM_015048.1	c.5699A>G, p.(Tyr1900Cys)	Heterozygous	Missense	17.88	Likely pathogenic	Intellectual developmental disorder with seizures and language delay	# 619000
71	SETD5	NM_001080517.1	c.2154del, p.(Val719Leufs*18)	Heterozygous	Frameshift		Pathogenic	Mental retardation, autosomal dominant 23	# 615761
72	SHANK3	NM_033517.1	c.3679dup, p.(Ala1227Glyfs*69)	Heterozygous	Frameshift		Pathogenic	Phelan-McDermid syndrome	# 606232
73	SLC2A1	NM_006516.2	c.732del, p.(Met244Ilefs*8)	Heterozygous	Frameshift		Pathogenic	GLUT1 deficiency syndrome 1	# 606777
74	SLC6A1	NM_003042.3	c.149G>T, p.(Arg50Leu)	Heterozygous	Missense	24.9	Likely pathogenic	Myoclonic-atonic epilepsy	# 616421
75	SMARCA4	NM_001128849.1	c.1675G>A, p.(Glu559Lys)	Heterozygous	Missense	34	Likely pathogenic	Coffin–Siris syndrome 4	# 614609

TABLE 1 (Continued)

Individual	Gene/locus	Transcript	Variant	Zygosity	Variant type	CADD score	ACMG classification	Diagnosis	OMIM phenotype
76	SMC1A	NM_001281463.1	c.587G>C, p.(Arg196Pro)	Heterozygous	Missense	23.9	Likely pathogenic	Cornelia de Lange syndrome 2	# 300590
77	SMC1A	NM_006306.3	c.3497A>C, p.(Asn1166Thr)	Heterozygous	Missense	26.5	Pathogenic	Cornelia de Lange syndrome 2	# 300590
78	SOX11	NM_003108.3	c.146 T>G, p.(Ile49Ser)	Heterozygous	Missense	28.6	Likely pathogenic	Coffin-Siris syndrome 9	# 615866
79	SPTBN2	NM_006946.2	c.1052G>C, p.(Arg351Pro)	Heterozygous	Missense	34	Likely pathogenic	Spinocerebellar ataxia 5	# 600224
80	STAG2	NM_001042749	c.2860C>T, p.(Arg954Cys)	Hemizygous	Missense	32	Likely pathogenic	Mullegama-Klein-Martinez syndrome	# 301022
81	STX1B	NM_052874.3	c.165dup, p.(Gln56Thrfs*3)	Heterozygous	Frameshift		Pathogenic	Generalized epilepsy with febrile seizures plus, type 9	# 616172
82	STXBP1	NM_001032221.3	c.1261G>T, p.(Glu421*)	Heterozygous	Nonsense	47	Pathogenic	Epileptic encephalopathy, early infantile, 4	# 612164
83	TBL1XR1	NM_024665.4	c.799G>T, p.(Gly267Cys)	Heterozygous	Missense	34	Pathogenic	Mental retardation, autosomal dominant 41	# 616944
84	TLK2	NM_006852.3	c.968+1G>C, p.?	Heterozygous	Splice	25.7	Pathogenic	Mental retardation, autosomal dominant 57	# 618050
85	TRIO	NM_007118.2	c.3232C>T, p.(Arg1078Trp)	Heterozygous	Missense	32	Likely pathogenic	Mental retardation, autosomal dominant 44	# 617061
86	TUBB	NM_178014.2	c.139A>G, p.(Ile47Val)	Heterozygous	Missense	18.88	Likely pathogenic	Cortical dysplasia, complex, with other brain malformations 6	# 615771
87	WAC	NM_016628.4	c.1890_1892del, p.(Gln632del)	Heterozygous	Indel		Likely pathogenic	Desanto-Shinawi syndrome	# 616708
88	YWHAG	NM_012479.3	c.395G>A, p.(Arg132His)	Heterozygous	Missense	33	Pathogenic	Epileptic encephalopathy, early infantile, 56	# 617665
89	ZC4H2	NM_018684.3	c.22_23del, p.(Met8Valfs*7)	Heterozygous	Frameshift		Pathogenic	Wieacker-Wolff syndrome, female-restricted	# 301041
90	ZEB2	NM_001171653.1	c.353_357del; p.(Ser118Phefs*2)	Heterozygous	Frameshift		Pathogenic	Mowat-Wilson syndrome	# 235730
91	ZEB2	NM_014795.3	c.2761C>T, p.(Arg921*)	Heterozygous	Nonsense	39	Pathogenic	Mowat-Wilson syndrome	# 235730
92	ZEB2	NM_014795.3	c.770_771del, p.(Glu257Alafs*22)	Heterozygous	Frameshift		Pathogenic	Mowat-Wilson syndrome	# 235730
93	ZEB2	NM_014795.3	c.899A>G, p.(His300Arg)	Heterozygous	Missense	24.5	Likely pathogenic	Mowat-Wilson syndrome	# 235730

Abbreviation: CNVs, Copy number variations.

[a]The variant was identified as low-level mosaicism in the mother (in 1/216 reads, maternal DNA derived from blood).

majority of them occurring only once (n = 58/72, 79.2%). The most commonly affected gene was *ZEB2* (n = 4/72, 5.6%) associated with "Mowat-Wilson syndrome", followed by *ARID1B* (n = 3/72, 4.2%), *GNAO1* (n = 3/72, 4.2%), *KMT2B* (n = 3/72, 4.2%) and *PURA* (n = 3/72, 4.2%). Disease-causing variants in nine different X-linked genes comprising *DDX3X* (n = 2), *MSL3* (n = 2), *SMC1A* (n = 2), *CDKL5* (n = 1), *HNRNPH2* (n = 1), *NONO* (n = 1), *PDHA1* (n = 1), *STAG2* (n = 1), and *ZC4H2* (n = 1) were detected. The spectrum of genes containing disease-causing *de novo* variants is visualized in Figure 2(B). Except for one variant in *GNAO1* (NM_020988.3:c.625C>T, p.(Arg209Cys)), no recurrent variants were observed. More than half of all *de novo* variants (n = 50/93, 53.8%) were novel at the time of data interpretation and had not yet been published. All *de novo* variants were absent from the gnomAD as well as from the Database of Genomic Variants (DGV).[25] Table 1 gives an overview of all disease-causing *de novo* variants identified in this study, including the associated disorder.

We systematically evaluated constraint metrics (pLIs and Z-scores) for all genes containing (likely) pathogenic *de novo* variants (excluding CNVs spanning more than one gene). We observed that the majority of genes (n = 58/67, 86.6%) showed a pLI score > 0.9 indicating a high intolerance toward loss-of-function variants. 46/67 (68.7%) genes had a Z-score > 3.09 expressing a high constraint toward missense variants (Figure 2(C), Figure 2(D)). We further evaluated those five genes (*RHOBTB2*, *SPTBN2*, *KCNT1*, *IMPDH2*, *IFIH1*, *SOX11*) that did not show an overall constraint toward missense as well as toward loss-of-function variants (Z-scores ≤3.09 and pLIs ≤0.9). Apart from *SOX11*, whose pLI is most likely low due to the small gene size, we observed that pathogenic variants reported in those genes are all missense variants that cluster within or around a specific domain, in line with a region-specific high constraint (Table S2, Figure S2).

3.4 | Identification of novel candidate and disease genes

In cases without a definite molecular diagnosis, we sought to uncover (novel) candidate genes for NDDs. In summary, 22 different candidate genes were prioritized in 23 individuals. In the majority of individuals (n = 16), *de novo* variants in candidate genes for autosomal dominant inherited NDDs were found. Seven individuals harbored biallelic variants in candidate genes for autosomal recessive inherited NDDs. All nominated candidate genes were submitted to GeneMatcher. Six individuals were subsequently published within large collaborations connected through GeneMatcher and one individual was published as case report following two previous case descriptions, all together establishing six novel disease-associated genes for NDDs, namely *CYFIP2*, *KDM3B*, *IMPDH2*, *FITM2*, *RALGAPA1*, and *VARS*.[28-33] Those seven individuals were considered as solved and assigned to the overall yield (Supplemental Figure 1A). Furthermore, we published another three individuals from this study as single case reports proposing three novel candidate genes for NDDs (*CAMK4*, *POU3F2*, *RBL2*).[34-36] A number of the nominated candidate genes from this study is included in ongoing studies with manuscripts in process and is therefore not listed in detail.

3.5 | Systematic reanalysis of unsolved cases

We reanalyzed existing exome data from all cases with negative results older than ≥1 year (August 2017–September 2019). In summary, we performed reanalysis of 80 initially negative cases using updated variant annotation and newly discovered disease-associated genes. We achieved a diagnosis in two additional individuals increasing the overall yield from n = 113/231 (48.9%) to n = 115/231 (49.8%). Both individuals harbored variants in genes associated with autosomal recessive disorders (*SMPD4*, *UGDH*)[37,38] that had not been described as disease-associated genes at the time of data interpretation and were therefore not prioritized as potentially relevant variants. Furthermore, two previously not prioritized candidate genes were identified (Supplemental Figure 1B).

4 | DISCUSSION

In this study, we present 231 individuals with different NDDs who underwent trio exome sequencing. We further delineate the associated genetic spectrum of NDDs and corroborate the burden of *de novo* variants in NDDs.

Performing trio exome sequencing in 231 individuals with NDDs and their parents, we achieved an overall yield of 49.8%. The diagnostic yield was significantly higher in individuals with NDD plus associated conditions in comparison to individuals with isolated NDD. Our results are in accordance with a recent meta-analysis (assessing 30 articles with data on molecular diagnostic yield of exome sequencing in individuals with NDDs) that reported a diagnostic yield of 31% for isolated NDD and 53% for NDD plus associated conditions.[16] One possible reason for this difference in diagnostic yields might be that a subgroup of those cases with isolated NDD has a multifactorial basis rather than a monogenic explanation.

With regard to disease burden of CNVs in NDDs, the observed proportion of 3% in our cohort was smaller than previous estimations ranging from 10% to 15%.[24,39] This discrepancy most likely originates from a depletion of our cohort for cases with CNVs due to prior genetic work up including chromosome microarray analysis in some cases. From a phenotype perspective, the vast majority of individuals in our study displayed additional, often predominant neurological features such as dystonia or seizures further underlining the convergence in the genetics of NDDs and other neurological comorbidities.[1,30,40]

Even though it is widely recognized that *de novo* variants in protein-coding genes constitute the major genetic cause of NDDs in outbred populations, the burden as well as the genetic spectrum *de novo* variants in NDDs have not been fully elucidated yet.[14] In terms of *de novo* variants, we made several key observations in our study: First, the frequency of disease-causing *de novo* variants of 40.3% (n = 93/231) aligns with the prevalence of 42% recently presented in a large sequencing study of individuals with NDDs,[13] emphasizing the utility of trio sequencing as a first-line strategy, in particular in sporadic cases.[41,42] Second, with the identification of 72 distinct molecular diagnoses in our cohort, we replicate the enormous genetic heterogeneity underlying NDDs which

challenges diagnostic determinations based on clinical examination alone, even in disorders actually considered as highly recognizable such as Mowat Wilson syndrome.[16,43] Those findings illustrate the advantage of exome sequencing over a targeted panel sequencing approach and further support exome sequencing as first-tier for the genetic testing of unexplained NDD in clinical practice.[16,44] Third, we expand the list of disease-causing variants in NDDs-associated genes with 50 previously unreported (likely) pathogenic variants facilitating variant classification in other cases. Last, we observed that in the majority of genes containing *de novo* variants the predicted constraint metrics indicated an overall high intolerance toward loss-of-function (pLI > 0.9) and/or missense variants (Z-score > 3.09) or a region-specific constraint illustrating the importance of constraint metrics for disease gene discovery and the understanding of disease mechanism.[25]

The percentage of autosomal recessive disorders in our NDD cohort (∼16%) which did not derive from a significant proportion of cases with a consanguineous background was surprisingly high in comparison to a previous study showing a low contribution (∼4%) of autosomal recessive disorders to NDD in patients with European ancestry.[45] The proportion of cases with syndromal NDD was higher in the subgroup with autosomal recessive inheritance (n = 19/19, 100%) in comparison with those with *de novo* variants (n = 89/93, 95.7%) raising the question whether inclusion criteria were different in our study in comparison with previously published cohorts.

As hundreds of novel causal genes for rare NDDs still await discovery,[5] we also aimed to elucidate novel disease-associated genes for NDDs leading to the prioritization of more than 20 different candidate genes in our cohort of 231 individuals. A number of the nominated candidate genes have already resulted in publication as novel disease-associated genes,[28,29,31] once more emphasizing the potential of international data sharing and cooperation.[46,47] Most important, we illustrate that a parent-offspring trio approach is also a powerful tool for the discovery of novel disease-associated genes as it facilitates the prompt identification of *de novo* variants and assignment of zygosity for inherited variants.[42] Given the fact that our overall diagnostic yield did not include individuals with findings in new candidate genes, some of which are currently in preparation for publication, we furthermore anticipate that the actual number of molecular diagnoses in our cohort is going to increase.

The discovery of gene-disease and variant-disease associations is continually growing necessitating regular reevaluation of unsolved exomes.[48,49] In line with previous studies demonstrating an improved diagnostic yield by systematic reanalysis of existing data,[48,50] we achieved a definitive diagnosis in two additional individuals (among 80 reanalyzed individuals with initial negative results). Beyond, reanalysis in our cohort lead to the identification of two novel candidate genes for NDDs highlighting the potential of subsequent reanalysis also for disease gene discovery.[41,51]

In summary, we consolidate the contribution and genetic heterogeneity of *de novo* variants in NDDs highlighting trio exome sequencing as an excellent diagnostic tool for rare NDDs. Besides, we illustrate the potential of a trio-approach for candidate gene discovery and the power of systematic reanalysis of unsolved cases.

ORCID

Theresa Brunet https://orcid.org/0000-0002-5183-780X
Gloria Leszinski https://orcid.org/0000-0002-7882-6721
Dominik S. Westphal https://orcid.org/0000-0003-4870-9863
Petra Pavelekova https://orcid.org/0000-0003-3071-5034
Felix Distelmaier https://orcid.org/0000-0003-4304-7848
Matias Wagner https://orcid.org/0000-0002-4454-8823

REFERENCES

1. Moreno-De-Luca A, Myers SM, Challman TD, Moreno-De-Luca D, Evans DW, Ledbetter DH. Developmental brain dysfunction: revival and expansion of old concepts based on new genetic evidence. *Lancet Neurol.* 2013;12(4):406-414.
2. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders: Diagnostic and Statistical Manual of Mental Disorders*. 5. Arlington, VA; American Psychiatric Association; 2013.
3. D'Haene E, Vergult S. Interpreting the impact of noncoding structural variation in neurodevelopmental disorders. *Genet Med.* 2021.23(1):34–46.
4. Kochinke K, Zweier C, Nijhof B, et al. systematic phenomics analysis deconvolutes genes mutated in intellectual disability into biologically coherent modules. *Am J Hum Genet.* 2016;98(1):149-164.
5. Kaplains J, Samocha KE, Wiel L, et al. Evidence for 28 genetic disorders discovered by combining healthcare and research data. *Nature.* 2020;586(7831):757–762.
6. de Ligt J, Willemsen MH, van Bon BW, et al. Diagnostic exome sequencing in persons with severe intellectual disability. *N Engl J Med.* 2012;367(20):1921-1929.
7. Epi KC, Epilepsy Phenome/Genome P, Allen AS, et al. De novo mutations in epileptic encephalopathies. *Nature.* 2013;501(7466):217-221.
8. Gilissen C, Hehir-Kwa JY, Thung DT, et al. Genome sequencing identifies major causes of severe intellectual disability. *Nature.* 2014;511 (7509):344-347.
9. Iossifov I, O'Roak BJ, Sanders SJ, et al. The contribution of de novo coding mutations to autism spectrum disorder. *Nature.* 2014;515 (7526):216-221.
10. Iossifov I, Ronemus M, Levy D, et al. De novo gene disruptions in children on the autistic spectrum. *Neuron.* 2012;74(2):285-299.
11. O'Roak BJ, Vives L, Girirajan S, et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. *Nature.* 2012;485(7397):246-250.
12. Rauch A, Wieczorek D, Graf E, et al. Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study. *Lancet.* 2012;380(9854):1674-1682.

13. Deciphering Developmental Disorders S. Prevalence and architecture of de novo mutations in developmental disorders. *Nature*. 2017;542 (7642):433-438.

14. Coe BP, Stessman HAF, Sulovari A, et al. Neurodevelopmental disease genes implicated by de novo mutation and copy number variation morbidity. *Nat Genet*. 2019;51(1):106-116.

15. Kohler S, Carmody L, Vasilevsky N, et al. Expansion of the human phenotype ontology (HPO) knowledge base and resources. *Nucleic Acids Res*. 2019;47(D1):D1018-D1027.

16. Srivastava S, Love-Nichols JA, Dies KA, et al. Meta-analysis and multi-disciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders. *Genet Med*. 2019;21(11):2413-2421.

17. Li H. A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data. *Bioinformatics*. 2011;27(21):2987-2993.

18. Plagnol V, Curtis J, Epstein M, et al. A robust model for read count data in exome sequencing experiments and implications for copy number variant calling. *Bioinformatics*. 2012;28(21):2747-2754.

19. Ye K, Schulz MH, Long Q, Apweiler R, Ning Z. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. *Bioinformatics*. 2009;25(21):2865-2871.

20. Wagner M, Berutti R, Lorenz-Depiereux B, et al. Mitochondrial DNA mutation analysis from exome sequencing-a more holistic approach in diagnostics of suspected mitochondrial disease. *J Inherit Metab Dis*. 2019;42(5):909-917.

21. Riggs ER, Andersen EF, Cherry AM, et al. Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the clinical genome resource (ClinGen). *Genet Med*. 2020;22(2):245-257.

22. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. 2015;17(5):405-424.

23. Abou Tayoun AN, Pesaran T, DiStefano MT, et al. Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion. *Hum Mutat*. 2018;39(11):1517-1524.

24. Strande NT, Riggs ER, Buchanan AH, et al. Evaluating the clinical validity of gene-disease associations: an evidence-based framework developed by the clinical genome resource. *Am J Hum Genet*. 2017; 100(6):895-906.

25. Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature*. 2020; 581(7809):434-443.

26. Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic variation in 60,706 humans. *Nature*. 2016;536(7616):285-291.

27. Fisher RA. On the interpretation of χ 2 from contingency tables, and the calculation of P. *J Royal Stat Soc*. 1922;85(1):87-94.

28. Zweier M, Begemann A, McWalter K, et al. Spatially clustering de novo variants in CYFIP2, encoding the cytoplasmic FMRP interacting protein 2, cause intellectual disability and seizures. *Eur J Hum Genet*. 2019;27(5):747-759.

29. Diets IJ, van der Donk R, Baltrunaite K, et al. De novo and inherited pathogenic variants in KDM3B cause intellectual disability, short stature, and facial dysmorphism. *Am J Hum Genet*. 2019;104(4):758-766.

30. Zech M, Jech R, Boesch S, et al. Monogenic variants in dystonia: an exome-wide sequencing study. *Lancet Neurol*. 2020;19(11):908-918.

31. Wagner M, Skorobogatko Y, Pode-Shakked B, et al. Bi-allelic variants in RALGAPA1 cause profound neurodevelopmental disability, muscular hypotonia, infantile spasms, and feeding abnormalities. *Am J Hum Genet*. 2020;106(2):246-255.

32. Riedhammer KM, Leszinski GS, Andres S, Strobl-Wildemann G, Wagner M. First replication that biallelic variants in FITM2 cause a complex deafness-dystonia syndrome. *Mov Disord*. 2018;33(10):1665-1666.

33. Siekierska A, Stamberger H, Deconinck T, et al. Biallelic VARS variants cause developmental encephalopathy with microcephaly that is recapitulated in vars knockout zebrafish. *Nat Commun*. 2019;10(1):708.

34. Westphal DS, Riedhammer KM, Kovacs-Nagy R, Meitinger T, Hoefele J, Wagner MA. De novo missense variant in POU3F2 identified in a child with global developmental delay. *Neuropediatrics*. 2018; 49(6):401-404.

35. Brunet T, Radivojkov-Blagojevic M, Lichtner P, Kraus V, Meitinger T, Wagner M. Biallelic loss-of-function variants in RBL2 in siblings with a neurodevelopmental disorder. *Ann Clin Transl Neurol*. 2020;7(3):390-396.

36. Zech M, Lam DD, Weber S, et al. A unique de novo gain-of-function variant in CAMK4 associated with intellectual disability and hyperkinetic movement disorder. *Cold Spring Harb Mol Case Stud*. 2018;4(6): a003293.

37. Hengel H, Bosso-Lefevre C, Grady G, et al. Loss-of-function mutations in UDP-glucose 6-dehydrogenase cause recessive developmental epileptic encephalopathy. *Nat Commun*. 2020;11(1):595.

38. Magini P, Smits DJ, Vandervore L, et al. Loss of SMPD4 causes a developmental disorder characterized by microcephaly and congenital arthrogryposis. *Am J Hum Genet*. 2019;105(4):689-705.

39. Kaminsky EB, Kaul V, Paschall J, et al. An evidence-based approach to establish the functional and clinical significance of copy number variants in intellectual and developmental disabilities. *Genet Med*. 2011; 13(9):777-784.

40. Heyne HO, Singh T, Stamberger H, et al. De novo variants in neurodevelopmental disorders with epilepsy. *Nat Genet*. 2018;50(7):1048-1053.

41. Wright CF, McRae JF, Clayton S, et al. Making new genetic diagnoses with old data: iterative reanalysis and reporting from genome-wide data in 1,133 families with developmental disorders. *Genet Med*. 2018;20(10):1216-1223.

42. Retterer K, Juusola J, Cho MT, et al. Clinical application of whole-exome sequencing across clinical indications. *Genet Med*. 2016;18(7):696-704.

43. Vissers LE, Gilissen C, Veltman JA. Genetic studies in intellectual disability and related disorders. *Nat Rev Genet*. 2016;17(1):9-18.

44. Mahler EA, Johannsen J, Tsiakas K, et al. Exome sequencing in children. *Dtsch Arztebl Int*. 2019;116(12):197-204.

45. Martin HC, Jones WD, McIntyre R, et al. Quantifying the contribution of recessive coding variation to developmental disorders. *Science*. 2018;362(6419):1161-1164.

46. Sobreira N, Schiettecatte F, Valle D, Hamosh A. GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. *Hum Mutat*. 2015;36(10):928-930.

47. Sobreira N, Schiettecatte F, Boehm C, Valle D, Hamosh A. New tools for Mendelian disease gene identification: PhenoDB variant analysis module; and GeneMatcher, a web-based tool for linking investigators with an interest in the same gene. *Hum Mutat*. 2015;36(4):425-431.

48. Wenger AM, Guturu H, Bernstein JA, Bejerano G. Systematic reanalysis of clinical exome data yields additional diagnoses: implications for providers. *Genet Med*. 2017;19(2):209-214.

49. Liu P, Meng L, Normand EA, et al. Reanalysis of clinical exome sequencing data. *N Engl J Med*. 2019;380(25):2478-2480.

50. Fung JLF, Yu MHC, Huang S, et al. A three-year follow-up study evaluating clinical utility of exome sequencing and diagnostic potential of reanalysis. *NPJ Genom Med*. 2020;5:37.

51. Schmitz-Abe K, Li Q, Rosen SM, et al. Unique bioinformatic approach and comprehensive reanalysis improve diagnostic yield of clinical exomes. *Eur J Hum Genet*. 2019;27(9):1398-1405.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of this article.